Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor antigen-specific cytotoxicity via genetically modified autologous tumor-infiltrating lymphocyte (TIL) (Genetically modified TIL therapy)
- Target
- Genetically modified TIL therapy
- Molecular classification
- Cellular Immunotherapy, Adoptive Cell Therapy, T-cell therapy
01
Overview
Tumor antigen-specific cytotoxicity via genetically modified autologous tumor-infiltrating lymphocyte (TIL) refers to a therapeutic strategy in which TILs—immune cells naturally present within a patient's tumor—are isolated, genetically engineered to enhance their ability to recognize and kill cancer cells expressing specific antigens, expanded ex vivo, and then reinfused into the patient. This approach is a form of adoptive cell therapy (ACT) that aims for highly personalized and targeted cancer treatment.
- Other names
- Genetically modified TILsEngineered TILsTIL gene therapyAdoptive cell therapy (ACT) with modified TILs
02
Mechanism of action
Genetically modified TILs recognize and kill cancer cells presenting specific antigens on their surface via MHC molecules.
03
Biological functions
CytotoxicityImmune responseTumor cell killingAntigen recognition
04
Disease associations
CancerMetastatic melanomaSolid tumorsHematologic malignancies
05
Safety considerations
Off-target effectsAutoimmunityCytokine release syndrome (CRS)On-target, off-tumor toxicityIntratumoral heterogeneityTumor microenvironment suppression
06
Interacting drugs
Interleukin-2 (IL-2)
1 more in the full profile.
07
Biomarkers
Tumor-associated antigen expressionTIL infiltration levelsMHC expressionTCR clonalityExpression of inhibitory receptors (e.g., PD-1, CTLA-4)
Beyond the preview
Go deeper on Tumor antigen-specific cytotoxicity via genetically modified autologous tumor-infiltrating lymphocyte (TIL) (Genetically modified TIL therapy).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor antigen-specific cytotoxicity via genetically modified autologous tumor-infiltrating lymphocyte (TIL) (Genetically modified TIL therapy).